Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis
- PMID: 15289563
- DOI: 10.1099/mic.0.27146-0
Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis
Abstract
Melioidosis is a severe infectious disease of animals and humans caused by the Gram-negative intracellular pathogen Burkholderia pseudomallei. An Inv/Mxi-Spa-like type III protein secretion apparatus, encoded by the B. pseudomallei bsa locus, facilitates bacterial invasion of epithelial cells, escape from endocytic vesicles and intracellular survival. This study investigated the role of the Bsa type III secretion system in the pathogenesis of melioidosis in murine models. B. pseudomallei bipD mutants, lacking a component of the translocation apparatus, were found to be significantly attenuated following intraperitoneal or intranasal challenge of BALB/c mice. Furthermore, a bipD mutant was attenuated in C57BL/6 IL-12 p40(-/-) mice, which are highly susceptible to B. pseudomallei infection. Mutation of bipD impaired bacterial replication in the liver and spleen of BALB/c mice in the early stages of infection. B. pseudomallei mutants lacking either the type III secreted guanine nucleotide exchange factor BopE or the putative effectors BopA or BopB exhibited varying degrees of attenuation, with mutations in bopA and bopB causing a significant delay in median time to death. This indicates that bsa-encoded type III secreted proteins may act in concert to determine the outcome of B. pseudomallei infection in mice. Mice inoculated with the B. pseudomallei bipD mutant were partially protected against subsequent challenge with wild-type B. pseudomallei. However, immunization of mice with purified BipD protein was not protective.
Similar articles
-
An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen.Mol Microbiol. 2002 Nov;46(3):649-59. doi: 10.1046/j.1365-2958.2002.03190.x. Mol Microbiol. 2002. PMID: 12410823
-
Burkholderia pseudomallei BopE suppresses the Rab32-dependent defense pathway to promote its intracellular replication and virulence.mSphere. 2024 Nov 21;9(11):e0045324. doi: 10.1128/msphere.00453-24. Epub 2024 Oct 21. mSphere. 2024. PMID: 39431830 Free PMC article.
-
BPSS1504, a cluster 1 type VI secretion gene, is involved in intracellular survival and virulence of Burkholderia pseudomallei.Infect Immun. 2014 May;82(5):2006-15. doi: 10.1128/IAI.01544-14. Epub 2014 Mar 4. Infect Immun. 2014. PMID: 24595140 Free PMC article.
-
Type III Secretion in the Melioidosis Pathogen Burkholderia pseudomallei.Front Cell Infect Microbiol. 2017 Jun 15;7:255. doi: 10.3389/fcimb.2017.00255. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28664152 Free PMC article. Review.
-
Melioidosis: molecular aspects of pathogenesis.Expert Rev Anti Infect Ther. 2014 Dec;12(12):1487-99. doi: 10.1586/14787210.2014.970634. Epub 2014 Oct 14. Expert Rev Anti Infect Ther. 2014. PMID: 25312349 Free PMC article. Review.
Cited by
-
Burkholderia vaccines: are we moving forward?Front Cell Infect Microbiol. 2013 Feb 5;3:5. doi: 10.3389/fcimb.2013.00005. eCollection 2013. Front Cell Infect Microbiol. 2013. PMID: 23386999 Free PMC article. Review.
-
Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization.Infect Immun. 2006 Mar;74(3):1706-11. doi: 10.1128/IAI.74.3.1706-1711.2006. Infect Immun. 2006. PMID: 16495542 Free PMC article.
-
Melioidosis: epidemiology, pathophysiology, and management.Clin Microbiol Rev. 2005 Apr;18(2):383-416. doi: 10.1128/CMR.18.2.383-416.2005. Clin Microbiol Rev. 2005. PMID: 15831829 Free PMC article. Review.
-
Development of vaccines against burkholderia pseudomallei.Front Microbiol. 2011 Sep 27;2:198. doi: 10.3389/fmicb.2011.00198. eCollection 2011. Front Microbiol. 2011. PMID: 21991263 Free PMC article.
-
A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.Clin Vaccine Immunol. 2014 May;21(5):747-54. doi: 10.1128/CVI.00119-14. Epub 2014 Mar 26. Clin Vaccine Immunol. 2014. PMID: 24671550 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources